Clinical trial testing vitamin and steroid combination in sepsis patients underway at Emory

October 11, 2018 by Janet Christenbury, Emory University
Credit: CC0 Public Domain

A new clinical trial at Emory University and 45 other sites around the U.S. will test a combination of vitamins and steroids in patients diagnosed with sepsis. Sepsis is caused by the body's overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure and death.

According to sepsis researchers, sepsis can account for 30 to 50 percent of all hospital deaths, making it the third leading cause of death in the U.S. Those numbers also make sepsis the most expensive reason for hospitalization, with annual expenditures exceeding $20 billion.

The VICTAS Study, which stands for VItamin C, Thiamine (also known as vitamin B1) And Steroids in Sepsis, is a multi-center, randomized, placebo-controlled, double-blind clinical trial. When a patient diagnosed with sepsis is hospitalized at one of the clinical trial sites, they will be assessed for the VICTAS trial and with their consent or consent from a family member, will be randomly selected to receive the vitamin/steroid cocktail or a placebo, in addition to clinical care provided by the treating team. The doctor, patient and family members will not know whether the patient received treatment or placebo until the end of the study. Study participants will be administered the or a placebo for four days, or until discharged from the intensive care unit (ICU), whichever comes first.

"The primary goals of this phase III study are to demonstrate the efficacy of combination therapy 1) in reducing the duration of cardiovascular and respiratory organ dysfunction or failure and 2) in reducing 30-day mortality in critically ill with sepsis," says Jon Sevransky, MD, MHS, FCCM, principal investigator of the multi-centered VICTAS Study and professor of medicine in the Division of Pulmonary, Allergy, Critical Care and Sleep, Emory University School of Medicine.

"There have been more than 100 phase III of pharmacological agents with the potential to improve sepsis outcomes, but few have worked, with only timely antibiotics demonstrating benefits for patients," says Sevransky. "We really want and need to find a better treatment for sepsis."

In 2017, positive results were published from a small study at an academic medical center in Virginia comparing the same combination therapy as in the VICTAS trial to similar control patients who did not receive combination therapy, but further study in a rigorous, randomized control trial setting was recommended.

The ingredients in the clinical trial's combination therapy include three inexpensive and readily available drugs found in hospital settings worldwide. Those factors help make this clinical trial appealing, according to researchers.

"We are familiar with the response of each of these drugs when treating patients diagnosed with sepsis," says David Wright, MD, professor and interim chair of the Department of Emergency Medicine at Emory and VICTAS co-principal investigator. "Vitamin C is a well-known antioxidant that reduces oxidative damage in the body. Patients with are known to have deficiency, so giving replacement thiamine can help strengthen the body. And we know corticosteroids play an important role in reducing inflammation in the body. Now, we will study how patients respond when using a combination of all three."

Researchers say there are very few side effects related to the three medications, making the combination safer and more convenient to test in a large population of people.

Explore further: Readily available drug cocktail can help prevent sepsis shock and death

More information: Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS): clinicaltrials.gov/ct2/show/NC … 350?cond=NCT03509350

Related Stories

Readily available drug cocktail can help prevent sepsis shock and death

June 26, 2017
Sepsis presents a major challenge for health care providers, especially in low-income countries where the mortality rate can exceed 60 percent. Even in advanced medical settings, sepsis is still very dangerous and accounts ...

Vitamin C trialled as life-saving treatment intensive care patients with sepsis

June 12, 2018
University of Otago, Christchurch researchers are teaming up with intensive care specialists to study whether intravenous infusions of vitamin C could be a life-saving treatment for patients with sepsis.

Critics demand stop to 'Guinea pig' sepsis clinical trial

September 26, 2018
(HealthDay)—A major non-profit advocacy group is asking that a large government trial comparing treatments for sepsis be shut down.

Combination antibiotic treatment does not result in less organ failure in adults with severe sepsis

May 21, 2012
Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on ...

Sepsis patients treated and released from emergency departments do well with outpatient follow-up

May 24, 2018
National guidelines assume that all patients who're diagnosed with clinical sepsis in an emergency department will be admitted to the hospital for additional care, but new research has found that many more patients are being ...

Immunocompromised patients with sepsis may face higher mortality at hospitals treating small numbers

June 1, 2018
Immunosuppressed patients with sepsis appear more likely to die if they are treated in a hospital caring for a relatively small number of these patients, according to new research published online in the Annals of the American ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

wagonerjc
not rated yet Oct 11, 2018
I find it sickening that the Marik Protocol, being tested in this Clinical trial instead of being adopted as a result of the retrospective study is resulting in a miss opportunity to save lives, while the medical industry delays for years to further test. At the very least patients should be offered the opportunity the try this successful, safe, and affordable protocol, even though it is not ' scientifically ' proven. Marik state's he has now treated over 700 sepsis patients and has only had one death due to Septic Shock. Is is a mountain of retrospective evidence that the Medial Industry chooses to ignore while allowing 250,000 deaths per year ( in the U.S. ) due to septic shock. By delaying and ignoring the opportunity to save lives and also provide a more robust recovery, great harm is being done.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.